Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Drugs for Schistosomiasis Market by Site (Intestinal, Urogenital), by Species Type (Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, Schistosoma guineensis, Schistosoma haematobium) and by Drug Type (Praziquantel, Metrifonate, Biltricide, Oxamniquine, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02369

Pages: NA

Charts: NA

Tables: NA

Schistosomiasis is a chronic and acute disease, which is caused by parasitic trematode worms of the genus Schistosoma. This parasite is transmitted to human body when people consume infested water that contains larval forms of the parasite. Hence, this disease is mainly witnessed among people who regularly work in agricultural, domestic, occupational, and recreational sectors (that expose them to infested water). Since past few years, the prevalence of schistosomiasis is increasing continuously.

This is evident from the estimates of WHO, which states that at least 218 million people required preventive treatment for schistosomiasis in 2015. Moreover, up till 2017, schistosomiasis transmission has been reported from 78 countries. Such high prevalence of the disease clearly showcases the need for effective treatment drugs that prevent schistosomiasis occurrence. Currently, praziquantel drug is the recommended treatment against all forms of schistosomiasis.

The factors that drive the growth of the global drugs for schistosomiasis market include rise in prevalence of schistosomiasis, lack of safe drinking water in developing countries, and inadequate healthcare facilities. However, high cost of drugs and stringent approval process restrains the market growth. Presence of large patient pool and unmet medical needs are anticipated to provide lucrative opportunities for the market growth.

The report segments the global drugs for schistosomiasis market based on site, species type, and drug type. In terms of site, the market is bifurcated into intestinal and urogenital. On the basis of species type, it is categorized into Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, Schistosoma guineensis, and Schistosoma haematobium. By drug type, it is classified into praziquantel metrifonate, biltricide, oxamniquine, and others. Geographic breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and LAMEA.

The major players operating in the market include Shin Poong Pharma.Co., Ltd., Merck & Co., Inc., Bayer AG, Egyptian International Pharmaceuticals Industries Co SAE (EIPICO), CBC Pharma., Taj Pharmaceuticals Ltd., V.H. Bhagat Pharmaceuticals Pvt. Ltd., VHB Life Science Inc., Samarth Pharma Pvt. Ltd., and Shreeji Pharma International. The other players of the market include Avanscure Lifesciences Pvt. Ltd., 3S Corporation Kancera AB, LondonPharma Ltd, Salvensis, Meher Distributors Pvt. Ltd., and Chemos GmbH & Co. KG.

Key Benefits

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global drugs for schistosomiasis market.
  • In-depth analysis has been done in this report by constructing market estimations for the key market segments.
  • Comprehensive analysis of factors that drive and restrict the growth of the global drugs for schistosomiasis market is provided.
  • Key market players within the drugs for schistosomiasis market are profiled in this report and their strategies are analyzed thoroughly, which help to understand competitive outlook of the market.

 Key Market Segments

  • By Site
    • Intestinal
    • Urogenital
  • By Species Type
    • Schistosoma mansoni
    • Schistosoma japonicum
    • Schistosoma mekongi
    • Schistosoma guineensis
    • Schistosoma haematobium
  • By Drug Type
    • Praziquantel
    • Metrifonate
    • Biltricide
    • Oxamniquine
    • Others
  • By Region
    • North America
    • Europe
    • Asia-Pacific
    • LAMEA

 
Key Market Players

  • Bayer AG
  • VHB Life Science Inc.
  • CBC Pharma.
  • Shin Poong Pharma.Co., Ltd.
  • Shreeji Pharma International
  • Merck and Co., Inc.
  • V.H. Bhagat Pharmaceuticals Pvt. Ltd.
  • Taj Pharmaceuticals Ltd.
  • Egyptian International Pharmaceuticals Industries Co SAE (EIPICO)
  • Samarth Pharma Pvt. Ltd.

 
The other players of the market include

  • Avanscure Lifesciences Pvt. Ltd.
  • 3S Corporation
  • Kancera AB
  • LondonPharma Ltd.
  • Salvensis
  • Meher Distributors Pvt. Ltd.
  • Chemos GmbH and Co. KG

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: DRUGS FOR SCHISTOSOMIASIS MARKET, BY SITE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Site

    • 4.2. Intestinal

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Urogenital

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: DRUGS FOR SCHISTOSOMIASIS MARKET, BY SPECIES TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Species Type

    • 5.2. Schistosoma Mansoni

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Schistosoma Japonicum

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Schistosoma Mekongi

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Schistosoma Guineensis

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Schistosoma Haematobium

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: DRUGS FOR SCHISTOSOMIASIS MARKET, BY DRUG TYPE

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Drug Type

    • 6.2. Praziquantel

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Metrifonate

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Biltricide

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Oxamniquine

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Others

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

  • CHAPTER 7: DRUGS FOR SCHISTOSOMIASIS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Site

      • 7.2.3. Market Size and Forecast, By Species Type

      • 7.2.4. Market Size and Forecast, By Drug Type

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Drugs For Schistosomiasis Market

        • 7.2.6.1. Market Size and Forecast, By Site
        • 7.2.6.2. Market Size and Forecast, By Species Type
        • 7.2.6.3. Market Size and Forecast, By Drug Type

      • 7.2.7. Canada Drugs For Schistosomiasis Market

        • 7.2.7.1. Market Size and Forecast, By Site
        • 7.2.7.2. Market Size and Forecast, By Species Type
        • 7.2.7.3. Market Size and Forecast, By Drug Type

      • 7.2.8. Mexico Drugs For Schistosomiasis Market

        • 7.2.8.1. Market Size and Forecast, By Site
        • 7.2.8.2. Market Size and Forecast, By Species Type
        • 7.2.8.3. Market Size and Forecast, By Drug Type

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Site

      • 7.3.3. Market Size and Forecast, By Species Type

      • 7.3.4. Market Size and Forecast, By Drug Type

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Drugs For Schistosomiasis Market

        • 7.3.6.1. Market Size and Forecast, By Site
        • 7.3.6.2. Market Size and Forecast, By Species Type
        • 7.3.6.3. Market Size and Forecast, By Drug Type

      • 7.3.7. Germany Drugs For Schistosomiasis Market

        • 7.3.7.1. Market Size and Forecast, By Site
        • 7.3.7.2. Market Size and Forecast, By Species Type
        • 7.3.7.3. Market Size and Forecast, By Drug Type

      • 7.3.8. Italy Drugs For Schistosomiasis Market

        • 7.3.8.1. Market Size and Forecast, By Site
        • 7.3.8.2. Market Size and Forecast, By Species Type
        • 7.3.8.3. Market Size and Forecast, By Drug Type

      • 7.3.9. Spain Drugs For Schistosomiasis Market

        • 7.3.9.1. Market Size and Forecast, By Site
        • 7.3.9.2. Market Size and Forecast, By Species Type
        • 7.3.9.3. Market Size and Forecast, By Drug Type

      • 7.3.10. UK Drugs For Schistosomiasis Market

        • 7.3.10.1. Market Size and Forecast, By Site
        • 7.3.10.2. Market Size and Forecast, By Species Type
        • 7.3.10.3. Market Size and Forecast, By Drug Type

      • 7.3.11. Russia Drugs For Schistosomiasis Market

        • 7.3.11.1. Market Size and Forecast, By Site
        • 7.3.11.2. Market Size and Forecast, By Species Type
        • 7.3.11.3. Market Size and Forecast, By Drug Type

      • 7.3.12. Rest Of Europe Drugs For Schistosomiasis Market

        • 7.3.12.1. Market Size and Forecast, By Site
        • 7.3.12.2. Market Size and Forecast, By Species Type
        • 7.3.12.3. Market Size and Forecast, By Drug Type

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Site

      • 7.4.3. Market Size and Forecast, By Species Type

      • 7.4.4. Market Size and Forecast, By Drug Type

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Drugs For Schistosomiasis Market

        • 7.4.6.1. Market Size and Forecast, By Site
        • 7.4.6.2. Market Size and Forecast, By Species Type
        • 7.4.6.3. Market Size and Forecast, By Drug Type

      • 7.4.7. Japan Drugs For Schistosomiasis Market

        • 7.4.7.1. Market Size and Forecast, By Site
        • 7.4.7.2. Market Size and Forecast, By Species Type
        • 7.4.7.3. Market Size and Forecast, By Drug Type

      • 7.4.8. India Drugs For Schistosomiasis Market

        • 7.4.8.1. Market Size and Forecast, By Site
        • 7.4.8.2. Market Size and Forecast, By Species Type
        • 7.4.8.3. Market Size and Forecast, By Drug Type

      • 7.4.9. South Korea Drugs For Schistosomiasis Market

        • 7.4.9.1. Market Size and Forecast, By Site
        • 7.4.9.2. Market Size and Forecast, By Species Type
        • 7.4.9.3. Market Size and Forecast, By Drug Type

      • 7.4.10. Australia Drugs For Schistosomiasis Market

        • 7.4.10.1. Market Size and Forecast, By Site
        • 7.4.10.2. Market Size and Forecast, By Species Type
        • 7.4.10.3. Market Size and Forecast, By Drug Type

      • 7.4.11. Thailand Drugs For Schistosomiasis Market

        • 7.4.11.1. Market Size and Forecast, By Site
        • 7.4.11.2. Market Size and Forecast, By Species Type
        • 7.4.11.3. Market Size and Forecast, By Drug Type

      • 7.4.12. Malaysia Drugs For Schistosomiasis Market

        • 7.4.12.1. Market Size and Forecast, By Site
        • 7.4.12.2. Market Size and Forecast, By Species Type
        • 7.4.12.3. Market Size and Forecast, By Drug Type

      • 7.4.13. Indonesia Drugs For Schistosomiasis Market

        • 7.4.13.1. Market Size and Forecast, By Site
        • 7.4.13.2. Market Size and Forecast, By Species Type
        • 7.4.13.3. Market Size and Forecast, By Drug Type

      • 7.4.14. Rest of Asia Pacific Drugs For Schistosomiasis Market

        • 7.4.14.1. Market Size and Forecast, By Site
        • 7.4.14.2. Market Size and Forecast, By Species Type
        • 7.4.14.3. Market Size and Forecast, By Drug Type

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Site

      • 7.5.3. Market Size and Forecast, By Species Type

      • 7.5.4. Market Size and Forecast, By Drug Type

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Drugs For Schistosomiasis Market

        • 7.5.6.1. Market Size and Forecast, By Site
        • 7.5.6.2. Market Size and Forecast, By Species Type
        • 7.5.6.3. Market Size and Forecast, By Drug Type

      • 7.5.7. South Africa Drugs For Schistosomiasis Market

        • 7.5.7.1. Market Size and Forecast, By Site
        • 7.5.7.2. Market Size and Forecast, By Species Type
        • 7.5.7.3. Market Size and Forecast, By Drug Type

      • 7.5.8. Saudi Arabia Drugs For Schistosomiasis Market

        • 7.5.8.1. Market Size and Forecast, By Site
        • 7.5.8.2. Market Size and Forecast, By Species Type
        • 7.5.8.3. Market Size and Forecast, By Drug Type

      • 7.5.9. UAE Drugs For Schistosomiasis Market

        • 7.5.9.1. Market Size and Forecast, By Site
        • 7.5.9.2. Market Size and Forecast, By Species Type
        • 7.5.9.3. Market Size and Forecast, By Drug Type

      • 7.5.10. Argentina Drugs For Schistosomiasis Market

        • 7.5.10.1. Market Size and Forecast, By Site
        • 7.5.10.2. Market Size and Forecast, By Species Type
        • 7.5.10.3. Market Size and Forecast, By Drug Type

      • 7.5.11. Rest of LAMEA Drugs For Schistosomiasis Market

        • 7.5.11.1. Market Size and Forecast, By Site
        • 7.5.11.2. Market Size and Forecast, By Species Type
        • 7.5.11.3. Market Size and Forecast, By Drug Type

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Shin Poong Pharma.Co., Ltd.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Merck And Co., Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Bayer AG

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Egyptian International Pharmaceuticals Industries Co SAE (EIPICO)

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. CBC Pharma.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Taj Pharmaceuticals Ltd.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. V.H. Bhagat Pharmaceuticals Pvt. Ltd.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. VHB Life Science Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Samarth Pharma Pvt. Ltd.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Shreeji Pharma International

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET, BY SITE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR INTESTINAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR UROGENITAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR SCHISTOSOMA MANSONI, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR SCHISTOSOMA JAPONICUM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR SCHISTOSOMA MEKONGI, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR SCHISTOSOMA GUINEENSIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR SCHISTOSOMA HAEMATOBIUM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR PRAZIQUANTEL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR METRIFONATE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR BILTRICIDE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR OXAMNIQUINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA DRUGS FOR SCHISTOSOMIASIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 20. NORTH AMERICA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 21. U.S. DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 22. U.S. DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 23. U.S. DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 24. CANADA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 25. CANADA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 26. CANADA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 29. MEXICO DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE DRUGS FOR SCHISTOSOMIASIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 33. EUROPE DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 36. FRANCE DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 39. GERMANY DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ITALY DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 41. ITALY DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 42. ITALY DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 45. SPAIN DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 46. UK DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 47. UK DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 48. UK DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 51. RUSSIA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 54. REST OF EUROPE DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC DRUGS FOR SCHISTOSOMIASIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 58. ASIA-PACIFIC DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 59. CHINA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 60. CHINA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 61. CHINA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 64. JAPAN DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 65. INDIA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 66. INDIA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 67. INDIA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 70. SOUTH KOREA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 73. AUSTRALIA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 76. THAILAND DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 79. MALAYSIA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 82. INDONESIA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA DRUGS FOR SCHISTOSOMIASIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 89. LAMEA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 92. BRAZIL DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 95. SOUTH AFRICA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 98. SAUDI ARABIA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 99. UAE DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 100. UAE DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 101. UAE DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 104. ARGENTINA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA DRUGS FOR SCHISTOSOMIASIS, BY SITE, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA DRUGS FOR SCHISTOSOMIASIS, BY SPECIES TYPE, 2025-2033 ($MILLION)
  • TABLE 107. REST OF LAMEA DRUGS FOR SCHISTOSOMIASIS, BY DRUG TYPE, 2025-2033 ($MILLION)
  • TABLE 108. SHIN POONG PHARMA.CO., LTD.: KEY EXECUTIVES
  • TABLE 109. SHIN POONG PHARMA.CO., LTD.: COMPANY SNAPSHOT
  • TABLE 110. SHIN POONG PHARMA.CO., LTD.: OPERATING SEGMENTS
  • TABLE 111. SHIN POONG PHARMA.CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 112. SHIN POONG PHARMA.CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 114. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 115. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 116. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 117. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. BAYER AG: KEY EXECUTIVES
  • TABLE 119. BAYER AG: COMPANY SNAPSHOT
  • TABLE 120. BAYER AG: OPERATING SEGMENTS
  • TABLE 121. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 122. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 123. EGYPTIAN INTERNATIONAL PHARMACEUTICALS INDUSTRIES CO SAE (EIPICO): KEY EXECUTIVES
  • TABLE 124. EGYPTIAN INTERNATIONAL PHARMACEUTICALS INDUSTRIES CO SAE (EIPICO): COMPANY SNAPSHOT
  • TABLE 125. EGYPTIAN INTERNATIONAL PHARMACEUTICALS INDUSTRIES CO SAE (EIPICO): OPERATING SEGMENTS
  • TABLE 126. EGYPTIAN INTERNATIONAL PHARMACEUTICALS INDUSTRIES CO SAE (EIPICO): PRODUCT PORTFOLIO
  • TABLE 127. EGYPTIAN INTERNATIONAL PHARMACEUTICALS INDUSTRIES CO SAE (EIPICO): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128. CBC PHARMA.: KEY EXECUTIVES
  • TABLE 129. CBC PHARMA.: COMPANY SNAPSHOT
  • TABLE 130. CBC PHARMA.: OPERATING SEGMENTS
  • TABLE 131. CBC PHARMA.: PRODUCT PORTFOLIO
  • TABLE 132. CBC PHARMA.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133. TAJ PHARMACEUTICALS LTD.: KEY EXECUTIVES
  • TABLE 134. TAJ PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
  • TABLE 135. TAJ PHARMACEUTICALS LTD.: OPERATING SEGMENTS
  • TABLE 136. TAJ PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
  • TABLE 137. TAJ PHARMACEUTICALS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 138. V.H. BHAGAT PHARMACEUTICALS PVT. LTD.: KEY EXECUTIVES
  • TABLE 139. V.H. BHAGAT PHARMACEUTICALS PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 140. V.H. BHAGAT PHARMACEUTICALS PVT. LTD.: OPERATING SEGMENTS
  • TABLE 141. V.H. BHAGAT PHARMACEUTICALS PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 142. V.H. BHAGAT PHARMACEUTICALS PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143. VHB LIFE SCIENCE INC.: KEY EXECUTIVES
  • TABLE 144. VHB LIFE SCIENCE INC.: COMPANY SNAPSHOT
  • TABLE 145. VHB LIFE SCIENCE INC.: OPERATING SEGMENTS
  • TABLE 146. VHB LIFE SCIENCE INC.: PRODUCT PORTFOLIO
  • TABLE 147. VHB LIFE SCIENCE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. SAMARTH PHARMA PVT. LTD.: KEY EXECUTIVES
  • TABLE 149. SAMARTH PHARMA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 150. SAMARTH PHARMA PVT. LTD.: OPERATING SEGMENTS
  • TABLE 151. SAMARTH PHARMA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 152. SAMARTH PHARMA PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. SHREEJI PHARMA INTERNATIONAL: KEY EXECUTIVES
  • TABLE 154. SHREEJI PHARMA INTERNATIONAL: COMPANY SNAPSHOT
  • TABLE 155. SHREEJI PHARMA INTERNATIONAL: OPERATING SEGMENTS
  • TABLE 156. SHREEJI PHARMA INTERNATIONAL: PRODUCT PORTFOLIO
  • TABLE 157. SHREEJI PHARMA INTERNATIONAL: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET
  • FIGURE 3. SEGMENTATION DRUGS FOR SCHISTOSOMIASIS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DRUGS FOR SCHISTOSOMIASIS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDRUGS FOR SCHISTOSOMIASIS MARKET
  • FIGURE 11. DRUGS FOR SCHISTOSOMIASIS MARKET SEGMENTATION, BY BY SITE
  • FIGURE 12. DRUGS FOR SCHISTOSOMIASIS MARKET FOR INTESTINAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. DRUGS FOR SCHISTOSOMIASIS MARKET FOR UROGENITAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. DRUGS FOR SCHISTOSOMIASIS MARKET SEGMENTATION, BY BY SPECIES TYPE
  • FIGURE 15. DRUGS FOR SCHISTOSOMIASIS MARKET FOR SCHISTOSOMA MANSONI, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. DRUGS FOR SCHISTOSOMIASIS MARKET FOR SCHISTOSOMA JAPONICUM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. DRUGS FOR SCHISTOSOMIASIS MARKET FOR SCHISTOSOMA MEKONGI, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. DRUGS FOR SCHISTOSOMIASIS MARKET FOR SCHISTOSOMA GUINEENSIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. DRUGS FOR SCHISTOSOMIASIS MARKET FOR SCHISTOSOMA HAEMATOBIUM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. DRUGS FOR SCHISTOSOMIASIS MARKET SEGMENTATION, BY BY DRUG TYPE
  • FIGURE 21. DRUGS FOR SCHISTOSOMIASIS MARKET FOR PRAZIQUANTEL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. DRUGS FOR SCHISTOSOMIASIS MARKET FOR METRIFONATE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. DRUGS FOR SCHISTOSOMIASIS MARKET FOR BILTRICIDE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. DRUGS FOR SCHISTOSOMIASIS MARKET FOR OXAMNIQUINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. DRUGS FOR SCHISTOSOMIASIS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: DRUGS FOR SCHISTOSOMIASIS MARKET
  • FIGURE 32. TOP PLAYER POSITIONING, 2024
  • FIGURE 33. SHIN POONG PHARMA.CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. SHIN POONG PHARMA.CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. SHIN POONG PHARMA.CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. MERCK AND CO., INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. BAYER AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. BAYER AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. BAYER AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. EGYPTIAN INTERNATIONAL PHARMACEUTICALS INDUSTRIES CO SAE (EIPICO): NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. EGYPTIAN INTERNATIONAL PHARMACEUTICALS INDUSTRIES CO SAE (EIPICO): REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. EGYPTIAN INTERNATIONAL PHARMACEUTICALS INDUSTRIES CO SAE (EIPICO): REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. CBC PHARMA.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. CBC PHARMA.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. CBC PHARMA.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. TAJ PHARMACEUTICALS LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. TAJ PHARMACEUTICALS LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. TAJ PHARMACEUTICALS LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. V.H. BHAGAT PHARMACEUTICALS PVT. LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. V.H. BHAGAT PHARMACEUTICALS PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. V.H. BHAGAT PHARMACEUTICALS PVT. LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. VHB LIFE SCIENCE INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. VHB LIFE SCIENCE INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. VHB LIFE SCIENCE INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. SAMARTH PHARMA PVT. LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. SAMARTH PHARMA PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. SAMARTH PHARMA PVT. LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. SHREEJI PHARMA INTERNATIONAL: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. SHREEJI PHARMA INTERNATIONAL: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. SHREEJI PHARMA INTERNATIONAL: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Drugs for Schistosomiasis Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved